| CD4+/CD8+ ratio | 50 mg ABX-464
(total=6) |
150 mg ABX-464
(total=16) |
Placebo
(total=8) |
Difference in LS means: 150 mg vs placebo (95% CI) | P value | |
|---|---|---|---|---|---|---|
| Day 0 | n | 6 | 16 | 8 | ||
| Mean (SD) | 1.36 (0.64) | 1.05 (0.38) | 1.05 (0.270) | |||
| Median [Range] | 1.21 [0.7–2.2] | 1.08 [0.5–1.8] | 0.97 [0.7–1.6] | |||
| LS mean | 1.05 | 1.05 | 0.00 (-0.31, 0.32) | 0.9836 | ||
| Day 7 | n | 6 | 16 | 7 | ||
| Mean (SD) | 1.29 (0.63) | 0.94 (0.28) | 1.03 (0.24) | |||
| Median [Range] | 1.23 [0.6–2.2] | 0.92 [0.5–1.5] | 1.03 [0.6–1.4] | |||
| LS mean | 0.94 | 1.03 | -0.09 (-0.34, 0.16) | 0.4723 | ||
| Day 14 | n | 5 | 15 | 7 | ||
| Mean (SD) | 1.18 (0.56) | 1.08 (0.39) | 1.16 (0.30) | |||
| Median [Range] | 1.03 [0.6–1.9] | 1.10 [0.5–1.6] | 0.99 [0.9–1.6] | |||
| LS mean | 1.08 | 1.16 | -0.08 (-0.42, 0.27) | 0.6478 | ||
| Day 21 | n | 6 | 15 | 8 | ||
| Mean (SD) | 1.30 (0.60) | 1.04 (0.38) | 1.20 (0.44) | |||
| Median [Range] | 1.27 [0.6–2.0] | 1.10 [0.6–1.8] | 1.08 [0.7–2.0] | |||
| LS mean | 1.04 | 1.20 | -0.16 (-0.52, 0.21) | 0.3767 | ||
| Day 25 | n | 3 | 9 | 6 | ||
| Mean (SD) | 1.53 (0.73) | 1.11 (0.28) | 1.15 (0.27) | |||
| Median [Range] | 1.88 [0.7–2.0] | 1.09 [0.7–1.6] | 1.10 [0.9–1.6] | |||
| LS mean | 1.11 | 1.15 | -0.04 (-0.36, 0.27) | 0.7628 | ||
| Day 28 | n | 6 | 13 | 7 | ||
| Mean (SD) | 1.39 (0.47) | 1.06 (0.30) | 1.08 (0.34) | |||
| Median [Range] | 1.48 [0.8–1.9] | 1.05 [0.6–1.6] | 0.97 [0.7–1.7] | |||
| LS mean | 1.06 | 1.08 | -0.03 (-0.33, 0.28) | 0.8581 | ||
n: number of participants; SD: standard deviation; LS mean: least squares mean; CI: confidence interval.
Viral load analysed using an analysis of variance (ANOVA) model with treatment as a fixed effect.